Abstract #3005
First-in-man Phase I study of the oral dual PI3K and mTORC1/2 inhibitor BEZ235 in patients with advanced solid tumors Howard Burris 1, Jordi Rodon 2, Sunil.
Therapeutic options for relapsed / refractory HER2 positive metastatic breast cancer
